{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:02:06Z","timestamp":1781614926334,"version":"3.54.5"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003The natural course of elevated factor VIII (FVIII) in patients with venous thromboembolism (VTE) and with or without inflammatory bowel disease (IBD) is not well described. Furthermore, the data on effectiveness and safety of extended anticoagulation in these patients are limited.<\/jats:p><jats:p>\n          Methods\u2003We performed a retrospective chart review of all patients with VTE who had an elevated FVIII level (&gt;1.5 IU\/mL) during a period of 16 years. FVIII levels, duration of anticoagulation, recurrent thromboembolic events, and bleeding requiring hospitalization were captured and compared between patients with and without IBD.<\/jats:p><jats:p>\n          Results\u2003Fourteen patients with IBD and 66 without IBD were followed for 8.0 years (standard deviation [SD]\u2009=\u2009\u2009\u00b1\u2009\u20093.5) and 5.6 years (SD\u2009=\u2009\u2009\u00b1\u2009\u20095.1), respectively. Among the 41 patients with repeat levels, FVIII remained elevated in most patients. None of the IBD patients had thromboembolic events or major bleeding during a mean of 5.6 years (SD\u2009=\u2009\u2009\u00b1\u2009\u20095.1) of anticoagulation. Three of five IBD patients who stopped anticoagulation had thromboembolic events at a median of 9 months after stopping, observed event rate of 12 per 100 patient-years. For the 66 non-IBD patients, the event rates of thromboembolism on and off anticoagulation were 1.6 and 7.2 per 100 patient-years, respectively, and of major bleeding on anticoagulation 0.8 per 100 patient-years.<\/jats:p><jats:p>\n          Conclusion\u2003Elevated FVIII in patients with VTE is often a persistent risk factor. The cohort with VTE and elevated FVIII that we analyzed appeared to have a favorable benefit\/risk ratio of extended anticoagulation.<\/jats:p>","DOI":"10.1055\/a-1827-7464","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T23:15:06Z","timestamp":1650323706000},"page":"e147-e153","source":"Crossref","is-referenced-by-count":3,"title":["High Factor VIII Levels and Recurrent Thromboembolism in Patients with and without Inflammatory Bowel Disease: A Retrospective Comparative Study"],"prefix":"10.1055","volume":"06","author":[{"given":"G E.","family":"Eagle","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-9043","authenticated-orcid":false,"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Obstetrics and Gynecology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"I M Rietveld","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","volume":"345","author":"T Koster","year":"1995","journal-title":"Lancet"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.thromres.2007.12.024","article-title":"D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis","volume":"122","author":"B Cosmi","year":"2008","journal-title":"Thromb Res"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"P A Kyrle","year":"2000","journal-title":"N Engl J Med"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1160\/TH05-01-0013","article-title":"Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - is it necessary to define a new upper reference range for factor VIII?","volume":"93","author":"P S Wells","year":"2005","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"P V Jenkins","year":"2012","journal-title":"Br J Haematol"},{"issue":"17","key":"ref7","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1182\/blood.2020008168","article-title":"Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia","volume":"137","author":"P Simioni","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1620\/tjem.132.93","article-title":"Studies on blood coagulation in ulcerative colitis and Crohn's disease","volume":"132","author":"K Mori","year":"1980","journal-title":"Tohoku J Exp Med"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0016-5085(75)80005-9","article-title":"Coagulation studies in ulcerative colitis and Crohn's disease","volume":"68","author":"A Lam","year":"1975","journal-title":"Gastroenterology"},{"issue":"17","key":"ref10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2169\/internalmedicine.46.0237","article-title":"Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis","volume":"46","author":"K Kume","year":"2007","journal-title":"Intern Med"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0016-5085(68)80041-1","article-title":"Hypercoagulability associated with chronic ulcerative colitis: changes in blood coagulation factors","volume":"54","author":"L C Lee","year":"1968","journal-title":"Gastroenterology"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/BF01072463","article-title":"Hemostatic alterations in inflammatory bowel disease: response to therapy","volume":"23","author":"A M Lake","year":"1978","journal-title":"Am J Dig Dis"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/00005176-198510000-00008","article-title":"Crohn's disease activity: assessment by factor VIII coagulation proteins","volume":"4","author":"S Zielen","year":"1985","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1055\/s-0037-1614553","article-title":"Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions","volume":"81","author":"P W Kamphuisen","year":"1999","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"T V Rohm","year":"2022","journal-title":"Immunity"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1467-789X.2002.00056.x","article-title":"Obesity, haemostasis and the fibrinolytic system","volume":"3","author":"I Mertens","year":"2002","journal-title":"Obes Rev"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1055\/s-0040-1722270","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a narrative review","volume":"47","author":"C Simion","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/jth.15491","article-title":"Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis","volume":"19","author":"F Khan","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"F Khan","year":"2019","journal-title":"BMJ"},{"issue":"19","key":"ref20","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"T L Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.51821\/84.1.910","article-title":"Venous thromboembolism in patients with inflammatory bowel disease: review of literature and practical algorithms","volume":"84","author":"L Coremans","year":"2021","journal-title":"Acta Gastroenterol Belg"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"M Harbord","year":"2016","journal-title":"J Crohn's Colitis"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/ibd\/izaa337","article-title":"Inflammatory bowel disease and risk of major bleeding during anticoagulation for venous thromboembolism","volume":"27","author":"S Scharrer","year":"2021","journal-title":"Inflamm Bowel Dis"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1827-7464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T14:17:26Z","timestamp":1660141046000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1827-7464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":24,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,4,27]]},"published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1827-7464","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,18]]},"published":{"date-parts":[[2022,4]]}}}